• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial.

作者信息

Ying Zhitao, Zou Dehui, Yang Haiyan, Wu Jianqiu, Guo Ye, Li Wenyu, Liu Hui, Wang Chris, Ma Laura, Yang Su, Zhou Zisong, Qin Yun, Song Yuqin, Zhu Jun

机构信息

Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.

Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China.

出版信息

Am J Hematol. 2022 Dec;97(12):E436-E438. doi: 10.1002/ajh.26711. Epub 2022 Sep 14.

DOI:10.1002/ajh.26711
PMID:36053875
Abstract
摘要

相似文献

1
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial.瑞马卡布他基因自体白细胞介素（Carteyva）在中国复发/难治性滤泡性淋巴瘤成人患者中的初步疗效和安全性：一项I/II期临床试验。
Am J Hematol. 2022 Dec;97(12):E436-E438. doi: 10.1002/ajh.26711. Epub 2022 Sep 14.
2
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.来那度胺和利妥昔单抗用于未经治疗的惰性淋巴瘤的安全性及活性：一项开放标签的2期试验
Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.
3
Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.复发/难治性滤泡性淋巴瘤的随机对照试验：一项系统评价和荟萃分析。
J Oncol Pharm Pract. 2016 Oct;22(5):666-78. doi: 10.1177/1078155215603230. Epub 2015 Aug 28.
4
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.idelalisib、来那度胺和利妥昔单抗在复发难治性淋巴瘤中的安全性和耐受性：肿瘤临床试验联盟A051201和A051202 1期试验
Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.
5
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.一项关于加利昔单抗（一种抗CD80单克隆抗体）联合利妥昔单抗治疗复发或难治性滤泡性淋巴瘤的I/II期研究。
Ann Oncol. 2007 Jul;18(7):1216-23. doi: 10.1093/annonc/mdm114. Epub 2007 Apr 29.
6
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.来那度胺治疗 B 细胞非霍奇金淋巴瘤的全面综述。
Ann Oncol. 2015 Aug;26(8):1667-77. doi: 10.1093/annonc/mdv102. Epub 2015 Feb 23.
7
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
8
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.利妥昔单抗抗CD20单克隆抗体疗法治疗非霍奇金淋巴瘤：再次治疗的安全性和疗效
J Clin Oncol. 2000 Sep;18(17):3135-43. doi: 10.1200/JCO.2000.18.17.3135.
9
Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.利妥昔单抗：在慢性淋巴细胞白血病、低级别或滤泡性淋巴瘤以及弥漫性大 B 细胞淋巴瘤中的应用综述。
Drugs. 2010 Jul 30;70(11):1445-76. doi: 10.2165/11201110-000000000-00000.
10
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.地塞米松、大剂量阿糖胞苷和顺铂联合利妥昔单抗作为复发或难治性侵袭性非霍奇金淋巴瘤患者的挽救治疗方案。
Cancer Invest. 2006 Oct;24(6):593-600. doi: 10.1080/07357900600814490.

引用本文的文献

1
Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study.嵌合抗原受体T细胞疗法联合自体干细胞移植治疗难治性/复发性B细胞淋巴瘤：一项单臂临床研究
Front Immunol. 2025 Feb 26;16:1532460. doi: 10.3389/fimmu.2025.1532460. eCollection 2025.
2
[How I treat relapsed/transformed follicular lymphoma].[我如何治疗复发/转化型滤泡性淋巴瘤]
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):983-988. doi: 10.3760/cma.j.issn.0253-2727.2023.12.003.